Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000406107

Medchemexpress LLC Ibutilide (fumarate) | 122647-32-9 | 99.7% | 50 MG
SDP

Catalog No. 5000406107
Encompass_Preferred

Ibutilide fumarate is an action potential-prolonging antiarrhythmic agent and a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. It is for research use only.

  • Potent IKr blocker with an EC50 value of 20 nM at +20 mV in atrial tumor myocytes (AT-1) cells.
  • Blocks IKr in cells expressing HERG+MDR1*1 to the same extent as cells expressing HERG alone (IC50: 22.5 nM vs 27.4 nM).
  • Cells expressing MDR1*7 show resistance (IC50: 105.3 nM vs 27.4 nM).
  • Prolongs cardiac repolarization in vitro and in vivo.
  • Cumulative doses (0.01, 0.02, and 0.05 mg/kg i.v., 10-min infusion) resulted in polymorphic and monomorphic non-sustained ventricular tachycardia in animal models.
  • Increased action potential duration at 90% (APD90) prolongation in congestive heart failure (CHF) dogs compared to controls at 0.01 mg/kg.

Catalog No. 50-004-06107 Supplier Medchemexpress LLC Supplier No. HYB038750MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Ibutilide fumarate is an action potential-prolonging antiarrhythmic agent and a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. It is for research use only.

  • Potent IKr blocker with an EC50 value of 20 nM at +20 mV in atrial tumor myocytes (AT-1) cells.
  • Blocks IKr in cells expressing HERG+MDR1*1 to the same extent as cells expressing HERG alone (IC50: 22.5 nM vs 27.4 nM).
  • Cells expressing MDR1*7 show resistance (IC50: 105.3 nM vs 27.4 nM).
  • Prolongs cardiac repolarization in vitro and in vivo.
  • Cumulative doses (0.01, 0.02, and 0.05 mg/kg i.v., 10-min infusion) resulted in polymorphic and monomorphic non-sustained ventricular tachycardia in animal models.
  • Increased action potential duration at 90% (APD90) prolongation in congestive heart failure (CHF) dogs compared to controls at 0.01 mg/kg.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.